Topic: Cardiovascular Liver-Kidney Metabolic Health and Cardiovascular Disease: Mechanisms, Biomarkers, and Therapeutic Strategies

Cardiometabolic diseases driven by metabolic dysfunction across the liver-kidney axis represent a critical global health challenge, characterized by a "two-hit" pathological framework involving proteotoxic stress and organelle dysfunction. Elucidating these mechanisms is essential, as chronic metabolic derangements affecting the liver and kidney often trigger irreversible cardiomyocyte loss and vascular stiffening through protein carbonylation and impaired mitochondrial quality control. The identification of early biomarkers, such as inter-organ communication mediators, metabolic memory signatures, exosomal cargo, and artificial intelligence (AI)-driven imaging features, is essential for detecting subclinical transitions before overt cardiovascular anomalies occur. Furthermore, the development of interventions including stimuli-responsive biomaterials and metabolic reprogramming strategies offers promising avenues for restoring cardiovascular homeostasis. Collectively, these advances may shift the clinical paradigm from single-organ symptom management to proactive multi-organ functional preservation.

Objectives and targeted topic content:

● To elucidate the molecular pathophysiology of cardiometabolic, renal, and hepatic crosstalk: Investigating how systemic metabolic anomalies and organelle dysfunction drive reciprocal injury across the heart, liver, and kidney axes.

● To identify early diagnostic signatures and biomarkers of inter-organ metabolic distress: Focusing on subclinical cardiovascular dysfunction originating from hepatic or renal injury, with particular emphasis on "metabolic memory" markers.

● To evaluate precision therapeutic strategies for restoring systemic homeostasis: Assessing emerging interventions, including stimuli-responsive delivery systems and metabolic reprogramming, that target cellular energy dysregulation and pathological inter-organ communication.

This Special Issue aims to advance the management of cardiometabolic diseases by shifting the focus toward inter-organ signaling and proteotoxic stress. By integrating early-warning biomarkers with precision, stimuli-responsive therapies, the contributions to this issue are expected to facilitate proactive clinical interventions that restore systemic homeostasis and prevent the progression from subclinical injury to irreversible multi-organ failure.